This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

PD-L1 Biomarker Testing Market

Market Insights on PD-L1 Biomarker Testing covering sales outlook, demand forecast & up-to-date key trends

PD-L1 Biomarker Testing Market By Product (PD-L1 22C3 Assay Kit, PD-L1 28-8 Assay Kit, PD-L1 SP142 Assay Kit, PD-L1 263 Assay Kit), Indication (NSCLS, Melanoma, Renal Cell Carcinoma, Gastrointestinal Tract Malignancy, Haematological Malignancies, Ovarian Cancer) & Region - Forecast 2022 - 2032

PD-L1 Biomarker Testing Market Outlook (2022-2032)

[318 Pages Report] The global PD-L1 biomarker testing market is projected to reach a valuation of US$ 597.9 Mn in 2022, with demand increasing at a robust 9.4% CAGR over the forecast period. Against this backdrop, the market valuation will total US$ 1.46 Bn by 2032.

Data Points

Market Insights

PD-L1 Biomarker Testing Market Value (2021)

US$ 541.6 Mn

PD-L1 Biomarker Testing Market Estimated Value (2022)

US$ 597.9 Mn

PD-L1 Biomarker Testing Market Projected Value (2032)

US$ 1.46 Bn

PD-L1 Biomarker Testing Market Value-based CAGR (2022-2032)

9.4%

PD-L1 Biomarker Testing Market Share of Top 5 Countries

75.1%

PD-L1 Biomarker Testing Market Key Players

F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Abcam plc and Shuwein Biotech Co. Ltd.

As per Future Market Insights (FMI), total sales in the NSCLS indications segment held about 61.9% of the global PD-L1 biomarker testing market share in 2021.

Manufacturers operating in the market are developing comprehensive cancer indications for available licensed biologics. Strategic approaches followed by the key players include an extension of indications through conduction of additional clinical investigations on the existing licensed biologics candidate.

Rising research activities for the treatment of several cancer indications are expected to bode well for the market. Increasing applications of biomarker testing across abundant and notorious tumour types, including trends in earlier-stage disease is anticipated to provide opportunities for key players to invest and research in the biomarker testing market.

The PD-L1 biomarker testing market accounted for nearly 2.0% of the global diagnostic biomarkers market worth US$ 30.1 Bn in 2021.

Customize this Report

Let us know your requirement to get
100% FREE customization

Sales Analysis Of PD-L1 Biomarker Testing From 2016 To 2020 Vs Market Outlook For 2021 To 2032

PD-L1 biomarker testing is identified as an early biomarker of immunotherapy clinical trials, which is a protein that indicates tumour presence. These tests are one of the most reliable tests for tumour detection in the market currently.

The reliability of testing is based on the presence of unique levels of PD-L1 protein in each individual, thus making it a dependable testing method in oncology management. Cancer diagnostics and analysis use PD-L1 biomarkers during testing to detect early stages of non-small cell lung cancer (NSCLS) and melanoma.

Rising prevalence of lung cancer worldwide is underpinning the need for effective biomarker tests. Increasing consumption of tobacco and smoking owing to changing lifestyles and stress is increasing the incidence of lung cancer.

Additionally, persistent low quality of air, presence of carcinogenic agents in the environment and air pollution are the major contributors for the high prevalence of lung associated cancers, which is driving demand for reliable PD-L1 biomarker tests.

PD-L1 Biomarker Testing Market Download Report Brochure

Rising awareness among the population regarding early cancer detection and diagnosis is propelling sales in the market. Increasing availability of high quality immunotherapy products globally will augment the growth in the market in the forthcoming years.

The prevalence of adverse conditions such as cancer relapse linked to frequent chemotherapy sessions and organ failure is spurring demand for advanced and novel technological solutions within the healthcare domain. This has resulted in higher reliance on cancer immunotherapy, which in turn is expected to drive sales of PD-L1 biomarker testing.

Backed by the aforementioned factors, sales in the market are projected to increase at a 9.4% CAGR, creating an absolute incremental opportunity of US$ 61.7 Mn over the forecast period.

What Are The Key Opportunities For PD-L1 Biomarker Testing Manufacturers?

The ongoing development of novel products and technologies with appropriate licensing for utilization is anticipated to propel the sales of PD-L1 biomarker testing in the forthcoming years. Strategic acquisitions between the leading players will provide significant opportunities for growth in terms of product differentiation.

Moreover, the development of reliable cancer screening and laboratory-based tests providing time effective diagnosis will bode well for the market. Growing applications of high medical value tests for more personalized medicine are expected to offer opportunities for growth for key market players.

Timely diagnosis of cancer is key, as misdiagnosis or delay in detection of lesions may lead to morbidity. Increasing usage of PD-L1 biomarker testing for early cancer diagnosis will augment the growth in the market over the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What Are The Factors Restraining Demand For PD-L1 Biomarker Testing?

Factors restraining the demand for PD-L1 biomarker testing include the challenges associated with testing and identification, validation of biomarkers and their implementation in molecular diagnostics. Moreover, trials associated with clone evolution and tumour heterogeneity identification, and testing of biomarkers is anticipated to have a negative impact on the growth in the market.

The shortage of qualified laboratory professionals will also hamper growth in the PD-L1 biomarker testing market as diagnostic laboratories utilize advanced equipment and automation. Despite the presence of advanced systems for ease of testing, critical errors related to the reliability of data across multiple platforms, as well as analogous challenges in analytical validation hamper will hamper sales.

Challenges in drug approval processes and tests by regulatory bodies and availability of limited reimbursement are significant barriers to molecular testing in several regions. These factors are favouring on-demand testing, which is set to impede the growth of the PD-L1 biomarker testing market in the coming years.

Country-Wise Insights

What is Driving the U.S. PD-L1 Biomarker Testing Market?

“Increasing Focus on Early Cancer Diagnosis in the U.S. Will Boost Sales of PD-L1 Biomarker Testing”

The U.S. dominated the North America PD-L1 biomarker testing market in 2021, holding 89.7% of the North America market shareHigh prevalence of lung cancer as well as associated chronic ailments in the country, along with increasing investments in the development of technologically advanced drugs and equipment in the oncology sector will boost the U.S. market over the forecast period.

Why is the U.K. PD-L1 Biomarker Testing Market Considered Lucrative?

“Growing Influx of Medical Tourism in the U.K. Will Bolster Demand for PD-L1 Biomarker Testing”

Sales in the U.K. are projected to increase at a 10% CAGR over the forecast period, accounting for a dominant share in the Europe PD-L1 testing market. The presence of governed predictive testing within the country by national and regional guidelines is anticipated to fuel sales in the market.

What Makes the China PD-L1 Biomarker Testing Market Attractive?

“Increasing Investments in the Medical Sector in China Will Boost Applications of PD-L1 Biomarker Testing”

As per FMI, China held 52.9% of the East Asia PD-L1 biomarker testing market in 2021, and sales are projected to increase at a 10.9% CAGR over the forecast period. Rising incidence of cancer cases in the country is underpinning the demand for PD-L1 biomarker testing.

Statistics presented by GLOBOCAN 2018 show that about 4,285,033 new cancer cases were diagnosed in China in 2018, which included 2,366,010 males and 1,919,023 females. These metrics support the transitive efforts by the country to present biomarker testing into the overall healthcare structure.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-Wise Insights

Which PD-L1 Biomarker Testing Product is Considered Highly Sought-After?

“Sales of PD-L1 22C3 Assay Kits Will Gain Traction”

Based on product type, demand in the PD-L1 22C3 assay kit segment is projected to increase at a 10.2% CAGR over the assessment period, accounting for 53% of the total market share by 2032. The effectiveness of PD-L1 22C3 assays during testing of non-small cell lung cancer, and patients’ positive response to immune checkpoint inhibitors will boost sales in this segment over the forecast period.

Why are Sales of PD-L1 Biomarker Testing in NSCLs Rising?

“Rising Incidence of Lung Cancer Across the Globe is Driving Demand for PD-L1 Biomarker Testing”

By indications, sales in the NSCLS segment is projected to increase at a 10.1% CAGR over the forecast period. The segment accounted for 61% of the global market share in 2021, and the trend is expected to continue in the forthcoming years. The availability of PD-L1 protein is the only biomarker which can guide treatment with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).

Which End User Benefits the Most by PD-L1 Biomarker Testing?

“Demand for PD-L1 Biomarker Testing in Cancer Research Institutes Will Remain high”

In terms of end user, total sales in the cancer research institutes accounted for about 43.2% of the global market share in 2021. With rising prevalence of cancer associated morbidity across the globe, the research and development activities for novel therapeutics for oncological indications within cancer research institutes is gaining traction.

Competitive Landscape

Key players are focusing on the development and launch of novel PD-L1 biomarkers for the treatment of different types of cancers. Market exclusivity and government incentives to promote new and innovative options for cancer treatment will create lucrative opportunities for market players.

Some recent developments include:

  • In June 2020, Merck received the FDA approval for second application for KEYTRUDA® (pembrolizumab), for the treatment of patients of all age groups suffering from metastatic tumour mutational burden-high (TMB-H).
  • In May 2020, Agilent Technologies' PD-L1 IHC 28-8 pharmDx was approved by the FDA for diagnosis of NSCLC.

Report Scope As Per PD-L1 Biomarker Testing Industry Analysis

Attribute

Details

Forecast Period

2022-2032

Historical Data Available for

2017-2021

Market Analysis

US$ Mn for Value

Key Regions Covered

North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa

Key Countries Covered

The U.S., Canada, Brazil, Mexico, Argentina, Germany, the U.K., France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa and South Africa

Key Market Segments Covered

Product, Indication, End User and Region

Key Companies Profiled

Pricing

Available upon Request

Key Market Segments Covered In PD-L1 Biomarker Testing Industry Research

By Product:

  • PD-L1 22C3 Assay Kit
  • PD-L1 28-8 Assay Kit
  • PD-L1 SP142 Assay Kit
  • PD-L1 263 Assay Kit

By Indication:

  • NSCLS
  • Melanoma
  • Renal Cell Carcinoma
  • Gastrointestinal tract Malignancy
  • Haematological Malignancies
  • Ovarian Cancer
  • Other

By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Institutes

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global PD-L1 biomarker testing market will total US$ 597.9 Mn in 2022, and is set to expand 2.4X over the forecast period.

The PD-L1 biomarker testing market is expected to reach US$ 1.46 Bn by the end of 2032, with sales growing at a 9.4% CAGR.

Growing burden of cancer, higher adoption of immunotherapy, and increasing approval for checkpoint inhibitor for the treatment of numerous cancer types are some of the key trends expected to drive the market.

The U.S., the U.K., Canada, Germany, and China are expected to drive demand in the PD-L1 biomarker testing market.

North America is one of the key markets for PD-L1 biomarker testing, with the U.S. expected to account over 90% of the North America market share during the forecast period.

Demand for PD-L1 biomarker testing in Europe is expected to grow at a 8.6% CAGR over the forecast period.

F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Abcam plc and Shuwein Biotech Co. Ltd. are the key players operating in the PD-L1 biomarker testing market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Roadmap/Treatment Evolution Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Product USPs / Features

    4.3. Strategic Promotional Strategies

5. COVID19 Crisis Analysis

    5.1. Current COVID19 Statistics and Probable Future Impact

    5.2. Current GDP Projection and Probable Impact

    5.3. Current Economic Projection as compared to 2008 financial analysis

    5.4. COVID19 and Impact Analysis

        5.4.1. Revenue by Product

        5.4.2. Revenue by Indication

        5.4.3. Revenue by End User

        5.4.4. Revenue by Country

    5.5. Recovery Scenario – Short term, Midterm and Long Term Impact

6. Market Background

    6.1. Macro-Economic Factors

    6.2. Forecast Factors - Relevance & Impact

        6.2.1. Top Companies Historical Growth

        6.2.2. Continuous Manufacturing Technology Innovation

        6.2.3. Increasing Prevalence of Cancer

    6.3. Market Dynamics

        6.3.1. Drivers

        6.3.2. Restraints

        6.3.3. Opportunity Analysis

7. Global PD-L1 Biomarker Testing Demand (in Volume Units) Analysis 2017-2021 and Forecast, 2022-2032

    7.1. Historical Market Volume (Units) Analysis, 2017-2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032

        7.2.1. Y-o-Y Growth Trend Analysis

8. Global PD-L1 Biomarker Testing Market - Pricing Analysis

    8.1. Regional Pricing Analysis by Product

    8.2. Global Average Pricing Analysis Benchmark

9. Global PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

    9.1. Historical Market Value (US$ Mn) Analysis, 2017-2021

    9.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032

        9.2.1. Y-o-Y Growth Trend Analysis

        9.2.2. Opportunity Analysis, 2022-2032

10. Global PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032, by Product

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis by Product, 2017–2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Product, 2022-2032

        10.3.1. PD-L1 22C3 Assay Kit

        10.3.2. PD-L1 28-8 Assay Kit

        10.3.3. PD-L1 SP142 Assay Kit

        10.3.4. PD-L1 SP263 Assay Kit

    10.4. Market Attractiveness Analysis by Product

11. Global PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032, by Indication 

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis by Indication, 2017–2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Indication, 2022-2032

        11.3.1. Non-small Cell Lung Cancer (NSCLC)

        11.3.2. Melanoma

        11.3.3. Renal Cell Carcinoma

        11.3.4. Gastrointestinal Tract Malignancies

        11.3.5. Ovarian Cancer

        11.3.6. Haematological Malignancies

    11.4. Market Attractiveness Analysis by Indication

12. Global PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032, by End User

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis by End User, 2017–2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by End User, 2022-2032

        12.3.1. Hospitals

        12.3.2. Diagnostic Laboratories

        12.3.3. Specialty Clinics

    12.4. Market Attractiveness Analysis by End User

13. Global PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032, by Region

    13.1. Introduction / Key Findings

    13.2. Historical Market Size (US$ Mn) Analysis by Region, 2017–2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2022-2032

        13.3.1. North America

        13.3.2. Latin America

        13.3.3. Europe

        13.3.4. East Asia

        13.3.5. South Asia

        13.3.6. Oceania

        13.3.7. Middle East and Africa

    13.4. Market Attractiveness Analysis by Region

14. North America PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032

        14.3.1. by Country

            14.3.1.1. U.S.

            14.3.1.2. Canada

        14.3.2. by Product

        14.3.3. by Indication

        14.3.4. by End User

    14.4. Market Attractiveness Analysis

    14.5. Drivers and Restraints - Impact Analysis

15. Latin America PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032

        15.3.1. by Country

            15.3.1.1. Brazil

            15.3.1.2. Mexico

            15.3.1.3. Argentina

            15.3.1.4. Rest of Latin America

        15.3.2. by Product

        15.3.3. by Indication

        15.3.4. by End User

    15.4. Market Attractiveness Analysis

    15.5. Drivers and Restraints - Impact Analysis

16. Europe PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032

        16.3.1. by Country

            16.3.1.1. Germany

            16.3.1.2. Italy

            16.3.1.3. France

            16.3.1.4. U.K.

            16.3.1.5. Spain

            16.3.1.6. BENELUX

            16.3.1.7. Russia

            16.3.1.8. Rest of Europe

        16.3.2. by Product

        16.3.3. by Indication

        16.3.4. by End User

    16.4. Market Attractiveness Analysis

    16.5. Drivers and Restraints - Impact Analysis

17. South Asia PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032

        17.3.1. by Country

            17.3.1.1. India

            17.3.1.2. Thailand

            17.3.1.3. Indonesia

            17.3.1.4. Malaysia

            17.3.1.5. Rest of South Asia

        17.3.2. by Product

        17.3.3. by Indication

        17.3.4. by End User

    17.4. Market Attractiveness Analysis

    17.5. Drivers and Restraints - Impact Analysis

18. East Asia PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021

    18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032

        18.3.1. by Country

            18.3.1.1. China

            18.3.1.2. Japan

            18.3.1.3. South Korea

        18.3.2. by Product

        18.3.3. by Indication

        18.3.4. by End User

    18.4. Market Attractiveness Analysis

    18.5. Drivers and Restraints - Impact Analysis

19. Oceania PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021

    19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032

        19.3.1. by Country

            19.3.1.1. Australia

            19.3.1.2. New Zealand

        19.3.2. by Product

        19.3.3. by Indication

        19.3.4. by End User

    19.4. Market Attractiveness Analysis

    19.5. Drivers and Restraints - Impact Analysis

20. Middle East and Africa PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021

    20.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032

        20.3.1. by Country

            20.3.1.1. GCC Countries

            20.3.1.2. South Africa

            20.3.1.3. Northern Africa 

            20.3.1.4. Rest of Middle East and Africa

        20.3.2. by Product

        20.3.3. by Indication

        20.3.4. by End User

    20.4. Market Attractiveness Analysis

    20.5. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries PD-L1 Biomarker Testing Market Analysis 2022 & 2032

    21.1. Introduction

        21.1.1. Market Value Proportion Analysis, by Key Countries

        21.1.2. Global Vs. Country Growth Comparison

    21.2. U.S. PD-L1 Biomarker Testing Market Analysis

        21.2.1. by Product

        21.2.2. by Indication

        21.2.3. by End User

    21.3. Canada PD-L1 Biomarker Testing Market Analysis

        21.3.1. by Product

        21.3.2. by Indication

        21.3.3. by End User

    21.4. Brazil PD-L1 Biomarker Testing Market Analysis

        21.4.1. by Product

        21.4.2. by Indication

        21.4.3. by End User

    21.5. Mexico PD-L1 Biomarker Testing Market Analysis

        21.5.1. by Product

        21.5.2. by Indication

        21.5.3. by End User

    21.6. Germany PD-L1 Biomarker Testing Market Analysis

        21.6.1. by Product

        21.6.2. by Indication

        21.6.3. by End User

    21.7. Italy PD-L1 Biomarker Testing Market Analysis

        21.7.1. by Product

        21.7.2. by Indication

        21.7.3. by End User

    21.8. U.K PD-L1 Biomarker Testing Market Analysis

        21.8.1. by Product

        21.8.2. by Indication

        21.8.3. by End User

    21.9. Spain PD-L1 Biomarker Testing Market Analysis

        21.9.1. by Product

        21.9.2. by Indication

        21.9.3. by End User

    21.10. BENELUX PD-L1 Biomarker Testing Market Analysis

        21.10.1. by Product

        21.10.2. by Indication

        21.10.3. by End User

    21.11. Russia PD-L1 Biomarker Testing Market Analysis

        21.11.1. by Product

        21.11.2. by Indication

        21.11.3. by End User

    21.12. India PD-L1 Biomarker Testing Market Analysis

        21.12.1. by Product

        21.12.2. by Indication

        21.12.3. by End User

    21.13. Thailand PD-L1 Biomarker Testing Market Analysis

        21.13.1. by Product

        21.13.2. by Indication

        21.13.3. by End User

    21.14. Indonesia PD-L1 Biomarker Testing Market Analysis

        21.14.1. by Product

        21.14.2. by Indication

        21.14.3. by End User

    21.15. Malaysia PD-L1 Biomarker Testing Market Analysis

        21.15.1. by Product

        21.15.2. by Indication

        21.15.3. by End User

    21.16. China PD-L1 Biomarker Testing Market Analysis

        21.16.1. by Product

        21.16.2. by Indication

        21.16.3. by End User

    21.17. Japan PD-L1 Biomarker Testing Market Analysis

        21.17.1. by Product

        21.17.2. by Indication

        21.17.3. by End User

    21.18. South Korea PD-L1 Biomarker Testing Market Analysis

        21.18.1. by Product

        21.18.2. by Indication

        21.18.3. by End User

    21.19. Australia PD-L1 Biomarker Testing Market Analysis

        21.19.1. by Product

        21.19.2. by Indication

        21.19.3. by End User

    21.20. New Zealand PD-L1 Biomarker Testing Market Analysis

        21.20.1. by Product

        21.20.2. by Indication

        21.20.3. by End User

    21.21. GCC PD-L1 Biomarker Testing Market Analysis

        21.21.1. by Product

        21.21.2. by Indication

        21.21.3. by End User

    21.22. South Africa PD-L1 Biomarker Testing Market Analysis

        21.22.1. by Product

        21.22.2. by Indication

        21.22.3. by End User

22. Market Structure Analysis

    22.1. Market Share Analysis of Top Players

    22.2. Market Presence Analysis

        22.2.1. By Regional footprint of Players

        22.2.2. Product foot print by Players

        22.2.3. Channel Foot Print by Players

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Competition Benchmarking

    23.3. Competition Deep Dive 

        23.3.1. F. Hoffmann-La Roche Ltd

            23.3.1.1. Overview

            23.3.1.2. Product Portfolio

            23.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.1.4. Sales Footprint

            23.3.1.5. Strategy Overview

                23.3.1.5.1. Marketing Strategy

                23.3.1.5.2. Product Strategy

                23.3.1.5.3. Channel Strategy

        23.3.2. Agilent Technologies, Inc.

        23.3.3. Abcam plc

        23.3.4. Shuwein Biotech Co. Ltd.

24. Assumptions and Acronyms Used

25. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global PD-L1 Biomarker Testing Market Analysis (US$) 2017–2021 and Forecast 2022–2032, by Product

Table 02(A): Global PD-L1 Biomarker Testing Market Volume (Unit) Analysis 2017–2021 and Forecast 2022–2032, By Product

Table 02(B): Global PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032

Table 03: Global PD-L1 Biomarker Testing Market Analysis 2017–2021 and Forecast 2022–2032, by Indication

Table 04: Global PD-L1 Biomarker Testing Market Analysis 2017–2021 and Forecast 2022–2032, by End User

Table 05: Global PD-L1 Biomarker Testing Market Analysis 2017–2021 and Forecast 2022–2032, by Region

Table 06: North America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 07: North America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 08: North America PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 09: North America PD-L1 Biomarker Testing Number of Tests (Thousands)Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 10: North America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication

Table 11: North America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User

Table 12: Latin America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 13: Latin America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 14: Latin America PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 15: Latin America PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 16: Latin America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication

Table 17: Latin America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User

Table 18: Europe PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 19: Europe PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 20: Europe PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 21: Europe PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 22: Europe PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication

Table 23: Europe PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User

Table 24: South Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 25: South Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 26: South Asia PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 27: South Asia PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 28: South Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication

Table 29: South Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User

Table 30: East Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 31: East Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 32: East Asia PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 33: East Asia PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 34: East Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication

Table 35: East Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User

Table 36: Oceania PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 37: Oceania PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 38: Oceania PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 39: Oceania PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 40: Oceania PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication

Table 41: Oceania PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User

Table 42: MEA PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 43: MEA PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 44: MEA PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 45: MEA PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product

Table 46: MEA PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication

Table 47: MEA PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 01: Global PD-L1 Biomarker Testing Market Volume (Units) Analysis, 2017–2021

Figure 02: Global PD-L1 Biomarker Testing Market Volume (Units) & Y-o-Y Growth (%) Analysis, 2022–2032

Figure 03: PD-L1 Biomarker Testing, Pricing Analysis per unit (US$), in 2021

Figure 04: PD-L1 Biomarker Testing, Pricing Forecast per unit (US$), in 2032

Figure 05: Global PD-L1 Biomarker Testing Market Value Analysis, 2017–2021

Figure 06: Global PD-L1 Biomarker Testing Market Forecast & Y-o-Y Growth, 2022–2032

Figure 07: Global PD-L1 Biomarker Testing Market Absolute $ Opportunity, 2022 –2032

Figure 08: Global PD-L1 Biomarker Testing Market Value Share (%) Analysis 2022 and 2032, by Product

Figure 09: Global PD-L1 Biomarker Testing Market Y-o-Y Growth (%) Analysis 2021-2032, by Product

Figure 10: Global PD-L1 Biomarker Testing Market Attractiveness Analysis 2022–2032, by Product

Figure 11: Global PD-L1 Biomarker Testing Market Value Share (%) Analysis 2022 and 2032, by Indication

Figure 12: Global PD-L1 Biomarker Testing Market Y-o-Y Growth (%) Analysis 2021-2032, by Indication

Figure 13: Global PD-L1 Biomarker Testing Market Attractiveness Analysis 2022–2032, by Indication

Figure 14: Global PD-L1 Biomarker Testing Market Value Share (%) Analysis 2022 and 2032, by End User

Figure 14: Global PD-L1 Biomarker Testing Market Y-o-Y Growth (%) Analysis 2021-2032, by End User

Figure 15: Global PD-L1 Biomarker Testing Market Attractiveness Analysis 2022–2032, by End User

Figure 17: Global PD-L1 Biomarker Testing Market Value Share (%) Analysis 2022 and 2032, by Region

Figure 18: Global PD-L1 Biomarker Testing Market Y-o-Y Growth (%) Analysis 2021-2032, by Region

Figure 19: Global PD-L1 Biomarker Testing Market Attractiveness Analysis 2022–2032, by Region

Figure 20: North America PD-L1 Biomarker Testing Market Value Analysis, 2017–2021

Figure 21: North America PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032

Figure 22: North America PD-L1 Biomarker Testing Market Value Share by Product (2022E)

Figure 23: North America PD-L1 Biomarker Testing Market Value Share by Indication (2022E)

Figure 24: North America PD-L1 Biomarker Testing Market Value Share by End User (2022E)

Figure 25: North America PD-L1 Biomarker Testing Market Value Share by Country (2022E)

Figure 26: North America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product

Figure 27: North America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication

Figure 28: North America PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User

Figure 29: North America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country

Figure 30: Latin America PD-L1 Biomarker Testing Market Value Analysis, 2017–2021

Figure 31: Latin America PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032

Figure 32: Latin America PD-L1 Biomarker Testing Market Value Share by Product (2022E)

Figure 33: Latin America PD-L1 Biomarker Testing Market Value Share by Indication (2022E)

Figure 34: Latin America PD-L1 Biomarker Testing Market Value Share by End User (2022E)

Figure 35: Latin America PD-L1 Biomarker Testing Market Value Share by Country (2022E)

Figure 36: Latin America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product

Figure 37: Latin America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication

Figure 38: Latin America PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User

Figure 39: Latin America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country

Figure 40: Europe PD-L1 Biomarker Testing Market Value Analysis, 2017–2021

Figure 41: Europe PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032

Figure 42: Europe PD-L1 Biomarker Testing Market Value Share by Product (2022E)

Figure 43: Europe PD-L1 Biomarker Testing Market Value Share by Indication (2022E)

Figure 44: Europe PD-L1 Biomarker Testing Market Value Share by End User (2022E)

Figure 45: Europe PD-L1 Biomarker Testing Market Value Share by Country (2022E)

Figure 46: Europe PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product

Figure 47: Europe PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication

Figure 48: Europe PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User

Figure 49: Europe PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country

Figure 50: South Asia PD-L1 Biomarker Testing Market Value Analysis, 2017–2021

Figure 51: South Asia PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032

Figure 52: South Asia PD-L1 Biomarker Testing Market Value Share by Product (2022E)

Figure 53: South Asia PD-L1 Biomarker Testing Market Value Share by Indication (2022E)

Figure 54: South Asia PD-L1 Biomarker Testing Market Value Share by End User (2022E)

Figure 55: South Asia PD-L1 Biomarker Testing Market Value Share by Country (2022E)

Figure 56: South Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product

Figure 57: South Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication

Figure 58: South Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User

Figure 59: South Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country

Figure 60: East Asia PD-L1 Biomarker Testing Market Value Analysis, 2017–2021

Figure 61: East Asia PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032

Figure 62: East Asia PD-L1 Biomarker Testing Market Value Share by Product (2022E)

Figure 63: East Asia PD-L1 Biomarker Testing Market Value Share by Indication (2022E)

Figure 64: East Asia PD-L1 Biomarker Testing Market Value Share by End User (2022E)

Figure 65: East Asia PD-L1 Biomarker Testing Market Value Share by Country (2022E)

Figure 66: East Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product

Figure 67: East Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication

Figure 68: East Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User

Figure 69: East Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country

Figure 70: Oceania PD-L1 Biomarker Testing Market Value Analysis, 2017–2021

Figure 71: Oceania PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032

Figure 72: Oceania PD-L1 Biomarker Testing Market Value Share by Product (2022E)

Figure 73: Oceania PD-L1 Biomarker Testing Market Value Share by Indication (2022E)

Figure 74: Oceania PD-L1 Biomarker Testing Market Value Share by End User (2022E)

Figure 75: Oceania PD-L1 Biomarker Testing Market Value Share by Country (2022E)

Figure 76: Oceania PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product

Figure 77: Oceania PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication

Figure 78: Oceania PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User

Figure 79: Oceania PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country

Figure 80: MEA PD-L1 Biomarker Testing Market Value Analysis, 2017–2021

Figure 81: MEA PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032

Figure 82: MEA PD-L1 Biomarker Testing Market Value Share by Product (2022E)

Figure 83: MEA PD-L1 Biomarker Testing Market Value Share by Indication (2022E)

Figure 84: MEA PD-L1 Biomarker Testing Market Value Share by End User (2022E)

Figure 85: MEA PD-L1 Biomarker Testing Market Value Share by Country (2022E)

Figure 86: MEA PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product

Figure 87: MEA PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication

Figure 88: MEA PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User

Figure 89: MEA PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country

Figure 90: Global PD-L1 Biomarker Testing Market Value Proportion Analysis, by Top Countries, 2022

Figure 91: Global PD-L1 Biomarker Testing Market, Global Vs. Country Growth Y-o-Y (%) Comparison, 2022-2032

Figure 92: U.S. Market Value Proportion Analysis

Figure 93: U.S. PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 94: U.S. PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 95: U.S. PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 96: Global Vs U.S. Growth Comparison

Figure 97: Canada Market Value Proportion Analysis

Figure 98: Canada PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 99: Canada PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 100: Canada PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 101: Global Vs Canada Growth Comparison

Figure 102: Brazil Market Value Proportion Analysis

Figure 103: Brazil PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 104: Brazil PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 105: Brazil PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 106: Global Vs Brazil Growth Comparison

Figure 107: Mexico Market Value Proportion Analysis

Figure 108: Mexico PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 109: Mexico PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 110: Mexico PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 111: Global Vs Mexico Growth Comparison

Figure 112: Argentina Market Value Proportion Analysis

Figure 113: Argentina PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 114: Argentina PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 115: Argentina PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 116: Global Vs Argentina Growth Comparison

Figure 117: U.K Market Value Proportion Analysis

Figure 118: U.K PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 119: U.K PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 120: U.K PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 121: Global Vs U.K Growth Comparison

Figure 122: Germany Market Value Proportion Analysis

Figure 123: Germany PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 124: Germany PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 125: Germany PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 126: Global Vs Germany Growth Comparison

Figure 127: France Market Value Proportion Analysis

Figure 128: France PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 129: France PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 130: France PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 131: Global Vs France Growth Comparison

Figure 132: Italy Market Value Proportion Analysis

Figure 133: Italy PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 134: Italy PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 135: Italy PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 136: Global Vs Italy Growth Comparison

Figure 137: Spain Market Value Proportion Analysis

Figure 138: Spain PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 139: Spain PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 140: Spain PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 141: Global Vs Spain Growth Comparison

Figure 142: Russia Market Value Proportion Analysis

Figure 143: Russia PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 144: Russia PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 145: Russia PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 146: Global Vs Russia Growth Comparison

Figure 147: BENULUX Market Value Proportion Analysis

Figure 148: BENULUX PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 149: BENULUX PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 150: BENULUX PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 151: Global Vs BENELUX Growth Comparison

Figure 152: India Market Value Proportion Analysis

Figure 153: India PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 154: India PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 155: India PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 156: Global Vs India Argentina Growth Comparison

Figure 157: Thailand Market Value Proportion Analysis

Figure 158: Thailand PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 159: Thailand PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 160: Thailand PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 161: Global Vs Thailand Growth Comparison

Figure 162: Malaysia Market Value Proportion Analysis

Figure 163: Malaysia PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 164: Malaysia PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 165: Malaysia PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 166: Global Vs Malaysia Growth Comparison

Figure 167: Indonesia Market Value Proportion Analysis

Figure 168: Indonesia PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 169: Indonesia PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 170: Indonesia PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 171: Global Vs Indonesia Growth Comparison

Figure 172: China Market Value Proportion Analysis

Figure 173: China PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 174: China PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 175: China PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 176: Global Vs China Growth Comparison

Figure 177: Japan Market Value Proportion Analysis

Figure 178: Japan PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 179: Japan PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 180: Japan PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 181: Global Vs Japan Growth Comparison

Figure 182: South Korea Market Value Proportion Analysis

Figure 183: South Korea PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 184: South Korea PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 185: South Korea PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 186: Global Vs South Korea Growth Comparison

Figure 187: Australia Market Value Proportion Analysis

Figure 188: Australia PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 189: Australia PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 190: Australia PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 191: Global Vs Australia Growth Comparison

Figure 192: New Zealand Market Value Proportion Analysis

Figure 193: New Zealand PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 194: New Zealand PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 195: New Zealand PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 196: Global Vs New Zealand Growth Comparison

Figure 197: Turkey Market Value Proportion Analysis

Figure 198: Turkey PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 199: Turkey PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 200: Turkey PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 201: Global Vs Turkey Growth Comparison

Figure 202: GCC Countries Market Value Proportion Analysis

Figure 203: GCC Countries PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 204: GCC Countries PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 205: GCC Countries PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 206: Global Vs GCC Countries Growth Comparison

Figure 207: South Africa Market Value Proportion Analysis

Figure 208: South Africa PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 209: South Africa PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 210: South Africa PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 211: Global Vs South Africa Growth Comparison

Figure 212: North Africa Market Value Proportion Analysis

Figure 213: North Africa PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032

Figure 214: North Africa PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032

Figure 215: North Africa PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032

Figure 216: Global Vs North Africa Growth Comparison

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

PD-L1 Biomarker Testing Market

Published : October 2020

Healthcare

PD-1/PD-L1 Inhibitors Market

Published : June 2017

Healthcare

Cancer Diagnostics Market

Published : March 2021

Healthcare

Clinical Trials Market

Published : July 2019

Google translate

PD-L1 Biomarker Testing Market